USA

The projects form part of Reckitt’s broader effort to increase production and bring research activities closer to its U.S. commercial operations.

The new company combines Kincell’s expertise in immune-cell technologies with Cellipont’s experience in stem cells, induced pluripotent stem cells (iPSCs), mesenchymal stromal cells (MSCs), dendritic cells, exosomes and emerging messenger RNA (mRNA) technologies.

Under the new agreement, Ori will work with its partner to modernise the manufacturing process for an autologous cell therapy.

QurCan will focus on developing and optimising genetic therapeutics using its delivery technology, while Lilly will take responsibility for advancing selected candidates through subsequent development stages.

The partnership complements existing mechanisms for supplying generic versions of lenacapavir and aims to address gaps in HIV prevention across the region.

Developed by Curium, Bexlutry is a lutetium-177 dotatate injection that references Novartis’ Lutathera, which is approved to treat gastroenteropancreatic neuroendocrine tumors (GEP NETs).

Exegenesis Bio designed EMC181 to improve the delivery of genetic medicines to muscle tissue while limiting exposure to the liver.

Following the transaction, the LSDx business will operate independently under the name Aluris Sciences.

Axogen expects to complete the transaction in the fourth quarter of 2026, adding BioCircuit’s NerveTape to its portfolio.

The facility will add to ABEC’s existing manufacturing operations in Bethlehem, Pennsylvania, and Springfield, Missouri, as well as its facilities in Fermoy and Kells, Ireland.